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Abstract
OBJECTIVE The aim of this study was to assess 
clozapine treatment in the local community with respect to 
patient monitoring during dispensing, patient compliance 
through prescription refills, presence of any other existing 
co-morbidities and presence of potential drug-drug 
interactions.
METHOD An audit on whether pharmacy personnel 
check patients’ white blood cell count and absolute 
neutrophil count prior to dispensing was performed. A total 
of 100 audits were carried out. A computer programme 
entitled ‘Pharmacy Dispensing System’ was used to 
assess patient compliance through prescription refills 
over a 3-month period. Another computer programme 
entitled ‘Schedule V’ was used to determine any other co-
morbidities. After determining the list of all the chronic 
medications, analysis of the presence of any potential drug-
drug interactions was undertaken. The ‘Drug Interaction 
Checker’, a drug interaction database provided by RxList, 
was used. This database classified potential drug-drug 
interactions into 3 categories namely minor, significant and 
serious.
KEY FINDINGS The white blood cell count and 
absolute neutrophil count were checked in all instances 
(N=100), however this intervention was not documented. 
Over a 3-month period, 78 out of 90 patients were 
compliant. Diabetes was the most common co-morbidity 
(n=15) and 76 patients receiving clozapine may be exposed 
to a potential drug-drug interaction. A total of 363 possible 
drug interactions were present in this group of patients. The 
most common type of potential drug-drug interaction fell 
in the ‘significant drug-drug interactions’ category (n=289).
CONCLUSION Patient monitoring was carried out, 
however documentation processes need to be elaborated. 
Identification of drug interactions is of utmost importance 
since certain interactions can be dangerous. Apart 
from detecting drug interactions, discussion with other 
healthcare professionals should be undertaken to assess 
the possibility of replacing such interacting drugs with 
alternative options. This measure should be carried out to 
promote patient safety.
KEYWORDS clozapine, patient monitoring, co-morbidities, 
drug-drug interactions 
Introduction
Clozapine is an atypical antipsychotic used in treatment-
resistant schizophrenia.1 In Malta patients who are on this 
drug and live in the community collect this medication 
from the Outpatients Pharmacy at Mater Dei Hospital. The 
maximum supply of clozapine dispensed is for 28 days. Since 
clozapine causes agranulocytosis2, the white blood cell 
count and absolute neutrophil count have to be checked 
prior to dispensing. The occurrence of potential drug-drug 
interactions is quite common in psychiatric patients since 
a large number of antipsychotics are metabolised through 
the hepatic cytochrome P450 system.3
The aim of this study was to review clozapine treatment 
in patients living in the community with respect to 
undertaking of patient monitoring during dispensing, 
assessment of patient compliance to clozapine treatment 
through prescription refills, determination of the presence 
of any other co-morbidities and assessment of the presence 
of potential drug-drug interactions.
Method
Approval to carry the study was obtained from the Chief 
Executive Officer and the Head of the Pharmacy Department 
at Mater Dei Hospital, as well as the Data Protection 
Officers of both Mater Dei Hospital and the Directorate of 
Pharmaceutical Affairs. 
A form entitled ‘Audit Form for Patient Monitoring’ was 
designed to evaluate patient monitoring. Observation of 
whether the pharmacist or pharmacy technician dispensing 
clozapine checked the white blood cell and absolute 
neutrophil count was undertaken. Another procedure 
observed was whether the pharmacist in charge of the high 
security store carries out double checking with regards to 
the mentioned parameters in the complete blood count. 
The audit was repeated 100 times. 
Since compliance to clozapine was assessed through 
prescription refills, the computer programme entitled 
‘Pharmacy Dispensing System’ was used. This programme 
is useful since it keeps records of any medication collected 
from Mater Dei Hospital. Clozapine compliance was 
retrospectively assessed over a 3-month period. 
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The Schedule V program is a computer programme which 
can be used to determine the list of chronic conditions the 
patient is suffering from. The number of co-morbidities 
present in each patient and the number of patients 
suffering from a particular co-morbidity was obtained. The 
medicines entitlement was used to obtain any other chronic 
medication/s the patient was taking during the selected 
3-month period. After determining the list of medications, 
analysis for the occurrence of any potential drug-drug 
interactions was carried out. The drug interaction database 
used in this study was the ‘Drug Interaction Checker’ 
provided by RxList.4 The frequency of patients experiencing 
a potential drug-drug interaction and the mean number of 
potential drug-drug interactions occurring in each patient 
were determined. The drug interaction database classified 
such potential drug-drug interactions into 3 categories, 
namely minor, significant and serious. The total number 
of potential drug-drug interactions and the total number 
of potential drug-drug interaction combinations in each 
category were determined. 
Results
The white blood cell count and absolute neutrophil count 
were checked in all instances (N=100) by the pharmacist or 
pharmacy technician dispensing the medication, as well as 
by the pharmacist in charge of the high security store.
 
A total of 90 patients were included in the study, where 
47 were female and 43 were male. The mean age of 
the patients was 50 years (range 20-80 years). Patient 
compliance to clozapine was assessed through prescription 
refills, where 78 out of 90 patients were compliant. The 
majority of patients (n=54) did not suffer from any other 
co-morbidities (Figure 1). 
The most common (n=15) co-morbidity present was 
diabetes (Figure 2). The co-morbidities classified as 
‘Others’ included gastro-oesophageal reflux disease 
(n=1), hypoparathyroidism (n=1), genetic dyslipidaemia 
(n=2), peripheral vascular disease (n=1), gastric ulcers 
(n=2), arrhythmias (n=1), myasthenia gravis (n=1) and 
cerebrovascular disease (n=1).
The most common drug taken by the patients in 
combination with clozapine was paroxetine (n=17) (Figure 3). 
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Figure 1: Number of co-morbidities present in clozapine-treated patients (N=90)
Figure 2: Frequency of the different co-morbidities in clozapine patients living in the community (N=90)
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A total of 363 potential drug-drug interactions were 
identified in these patients. Out of 90 patients, 76 patients 
could be exposed to drug interactions. The mean number 
of potential drug-drug interactions present in each patient 
is 4. ‘Significant’ drug-drug interactions (n=289) are the 
most common type of potential drug-drug interactions. 
This is followed by ‘minor’ drug-drug interactions (n=54) 
and ‘serious’ drug-drug interactions (n=20). 
Discussion
Even though the white blood cell and absolute neutrophil 
count were checked in all instances, this intervention was 
not documented. Documentation of an intervention is 
important since it provides a way for the pharmacist to be 
responsible for his or her actions. It also provides a means 
of communication with other healthcare professionals 
during the planning of patient care. Documentation 
must be complete, factual, current, and organised.5 The 
computer programme ‘Pharmacy Dispensing System’ can 
be used to document this intervention to ensure that good 
documentation is maintained. The person dispensing the 
medication can document this process under the remarks 
section by writing the values for the white blood cell 
and absolute neutrophil count and whether the values 
are within the required limits. When the transaction is 
complete, a sticker with this information, together with the 
amount of medications dispensed, is produced and fixed on 
the back of the patient’s Schedule V Card. The professional 
dispensing the medication can sign on this sticker, followed 
by a counter signature by the pharmacist who double 
checks this intervention. This procedure would ensure that 
the patient and health care professionals who view the 
patient’s Schedule V card would be aware that the patient’s 
white blood cell and absolute neutrophil count are being 
monitored.
 
There are various reasons which explain the reason for 
diabetes being a common occurrence in schizophrenic 
patients. Clozapine has various side-effects including 
hyperglycemia, weight gain, hypercholesterolemia and 
hypertriglyceridemia.6 These side-effects increase the 
patient’s risk of developing diabetes. Another reason why 
diabetes is the most common co-morbidity is that there is 
a relationship between schizophrenia and diabetes. It has 
been found that schizophrenic patients are 2 to 4 times 
more likely to develop diabetes.7 Another factor which 
contributes towards a high incidence of diabetes mellitus is 
the high occurrence of diabetes in the Maltese population.8 
The pharmacist should therefore monitor the patient for 
diabetes mellitus during dispensing. 
The occurrence of potential drug-drug interactions may 
lead to the need for hospitalisation. A study by Raschetti et 
al has shown that the frequency of visits to the emergency 
department due to drug-drug interactions represented 
3.8% of the total visits.9 Having a clinical pharmacist 
assigned to psychiatric consultants is recommended to 
reduce the potential occurrence of drug-related problems 
and to provide information about interactions to physicians 
and patients. At present, there are no clinical pharmacists 
forming part of the psychiatric team at Mater Dei Hospital. 
Pharmacists are in an ideal position to give advice about the 
occurrence of potential drug-drug interactions. 
A limitation of this study was the method chosen to 
determine patient compliance. The determination of the 
rate of prescription refills is not expensive and easy to 
carry out, however, this method is not as accurate as direct 
observation of patient compliance to treatment. Another 
limitation was that only chronic drugs which are collected 
for free were considered for the occurrence of potential 
drug-drug interactions. Drugs which the patient might 
purchase were not included.
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Figure 3: Frequency of the 6 most common drugs taken together with clozapine (N=90)
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Conclusion
Patient adherence to medication is necessary to achieve 
the maximal therapeutic benefit. Since certain drug-
drug interactions can be dangerous, it is important that 
interactions are detected. Besides detecting drug-drug 
interactions, discussion with other healthcare professionals 
regarding clozapine treatment and therapies used for co-
morbidities should be carried out to assess the possibility 
of replacing the interacting drug with alternative treatment 
options. The introduction of such a procedure will help to 
further promote patient safety.
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Having a clinical pharmacist assigned to  
psychiatric consultants is recommended to reduce  
the potential occurrence of drug-related problems and  
to provide information about interactions  
to physicians and patients. 
